The Contract Research, Development, and Manufacturing Organization Business Model to Drive Future Growth Potential
The analyst provides comprehensive insights into the global biologics contract development and manufacturing organization (bio-CDMO) market, including emerging trends, growth opportunities, and profiles of leading bio-CDMOs and their business model evolution. The growth of next-generation biologics and personalized therapies and the emergence of small and midsize biotechnology companies drive bio-CDMOs toward becoming end-to-end integrated service providers for better customer value creation. Next-generation biologics require outsourcing in the early stages of development. With limited or no in-house bioprocess development capacity for new modalities, big pharmaceutical firms and small and emerging biotechnology companies seek outsourcing for these services. To support the outsourcing demand, bio-CDMOs expand to provide contract research services, leading to their adoption of the CRDMO model: contract research, development, and manufacturing.
Company profiles included in this research service offer a brief overview of the bio-CDMO’s value proposition and strategic analysis. The report also emphasizes key strategic collaborations and expansion plans across the biopharmaceutical market. Recent expansion activities in the market reflect the increasing role of bio-CDMOs as a strategic partner in developing new modalities. Bio-CDMOs build capacity and capability to support modalities such as cell and gene therapy and mRNA. The biopharmaceutical market is skewed toward these modalities following the success of mRNA technology in COVID-19 vaccines and therapeutics.
Research Highlights
The research service also highlights the following:
- Role of bio-CDMOs in COVID-19 vaccine scale-up
- Key trends shaping the bio-CDMO industry
- In-house versus outsourcing manufacturing capacity of biologics
- Key themes driving collaborations/expansions
- Recent notable acquisitions and capacity expansions by leading bio-CDMOs
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AGC Biologics
- Boehringer Ingelheim BioXcellence™
- Catalent
- Lonza
- Samsung Biologics
- Thermo Fisher Scientific
- WuXi AppTec
- WuXi Biologics
